HKI 357
中文名称 | HKI 357 |
---|---|
中文同义词 | 化合物 T11569;化合物HKI-357;(E)-N-(4-((3-氯-4-((3-氟苄基)氧基)苯基)氨基)-3-氰基-7-乙氧基喹啉-6-基)-4-(二甲基氨基)丁-2-烯酰胺;HKI 357,ERBB2和EGFR的双重不可逆抑制剂 |
英文名称 | HKI 357 |
英文同义词 | HKI 357;2-Butenamide, N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-;(2E)-N-[[4-[[(3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;Inhibitor,HKI-357,ErbB-1,HER1,inhibit,NSCLCs,Epidermal growth factor receptor,HKI 357,EGFR,ERBB2,HKI357 |
CAS号 | 848133-17-5 |
分子式 | C31H29ClFN5O3 |
分子量 | 574.05 |
EINECS号 | |
相关类别 | |
Mol文件 | 848133-17-5.mol |
结构式 |
HKI 357 性质
沸点 | 747.6±60.0 °C(Predicted) |
---|---|
密度 | 1.34±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 在 DMSO 中溶解度为 100 mM,在乙醇中溶解度为 25 mM |
形态 | 粉末 |
酸度系数(pKa) | 12.37±0.43(Predicted) |
EGFR 34 nM (IC 50 ) |
ErbB2 33 nM (IC 50 ) |
HKI-357 (0.01-10 μM) is effective in suppressing ligand-induced EGFR autophosphorylation and its downstream signaling, as determined by AKT and MAPK phosphorylation in NCI-H1975 cells. HKI-357 also is effective in suppressing EGFR autophosphorylation (measured at residue Y1068), and AKT and MAPK phosphorylation in parental NCI-H1650 cells harboring the delE746-A750 EGFR mutation.
Western Blot Analysis
Cell Line: | NCI-H1975 bronchoalveolar cell line |
Concentration: | 0.01, 0.01, 0.1, 1 and 10 μM |
Incubation Time: | |
Result: | Suppressed ligand-induced EGFR autophosphorylation and its downstream signaling AKT and MAPK phosphorylation. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-103443 | HKI 357 HKI-357 | 848133-17-5 | 10mg | 2900元 |
2024/04/30 | HY-103443 | HKI 357 HKI-357 | 848133-17-5 | 50 mg | 9400元 |